|
|
Reference
|
|
|
Brodie, M.J., Schachter, S.C., Kwan, P. (2012) Fast facts: Epilepsy. Oxford, UK: Health Press Limited
|
|
|
Buck, M.L. (2016) Use of perampanel for refractory seizures in pediatric patients. Pediatr Pharmacother, 22(1): 1-4
|
|
 
|
Canafoglia, L., Ciano, C., Panzica, F., Scaioli, V., Zucca, C., Agazzi, P., Visani, E., Avanzini, G., Franceschetti, S. (2004) Sensorimotor cortex excitability in Unverricht-Lundborg disease and Lafora body disease. Neurology, 63(12): 2309-2315
|
|
|
Dinuzzo, M., Mangia, S., Maraviglia, B., Giove, F. (2015) Does abnormal glycogen structure contribute to increased susceptibility to seizures in epilepsy?. Metabolic Brain Disease, 30(1): 307-316
|
|
|
Dirani, M., Nasreddine, W., Abdulla, F., Beydoun, A. (2014) Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel. Epilepsy & Behavior Case Reports, 2: 164-166
|
|
|
Ettinger, A.B., LoPresti, A., Yang, H., Williams, B., Zhou, S., Fain, R., Laurenza, A. (2015) Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia, 56(8): 1252-1263
|
|
|
Franceschetti, S., Gambardella, A., Canafoglia, L., Striano, P., Lohi, H., Gennaro, E., Ianzano, L., Veggiotti, P., Sofia, V., Biondi, R., Striano, S., Gellera, C., Annesi, G., Madia, F. (2006) Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia, 47(3): 640-643
|
|
|
French, J.A., Krauss, G.L., Wechsler, R.T., Wang, X., DiVentura, B., Brandt, C., Trinka, E., O'Brien, T.J., Laurenza, A., Patten, A., Bibbiani, F. (2015) Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: A randomized trial. Neurology, 85(11): 950-957
|
|
|
Frucht, S.J., Leurgans, S.E., Hallett, M., Fahn, S. (2002) The unified myoclonus rating scale. Adv Neurol, 89: 361-76
|
|
|
Genton, P., Jovic, N.J., Lesca, G., Kecmanovic, M. (2015) Is adjunctive perampanel an option for intractable seizures in Lafora disease?. Epilepsia, 56(1): 57-8
|
|
|
Gentry, M.S., Guinovart, J.J., Minassian, B.A., Roach, P.J., Serratosa, J.M. (2018) Lafora disease offers a unique window into neuronal glycogen metabolism. Journal of Biological Chemistry, 293(19): 7117-7125
|
|
|
Goldsmith, D., Minassian, B.A. (2016) Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy & Behavior, 62: 132-135
|
|
|
Kecmanović, M., Jović, N., Keckarević-Marković, M., Keckarević, D., Stevanović, G., Ignjatović, P., Romac, S. (2016) Clinical and genetic data on Lafora disease patients of Serbian/Montenegrin origin. Clinical Genetics, 89(1): 104-108
|
|
|
Kecmanović, M., Keckarević-Marković, M., Keckarević, D., Stevanović, G., Jović, N., Romac, S. (2016) Genetics of Lafora progressive myoclonic epilepsy: Current perspectives. Application of Clinical Genetics, 9: 49-53
|
|
|
Krauss, G.L., Serratosa, J.M., Villanueva, V., Endziniene, M., Hong, Z., French, J., Yang, H., Squillacote, D., Edwards, H.B., Zhu, J., Laurenza, A. (2012) Randomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures. Neurology, 78(18): 1408-1415
|
|
|
Lagae, L., Villanueva, V., Meador, K.J., Bagul, M., Laurenza, A., Kumar, D., Yang, H. (2016) Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety. Epilepsia, 57(7): 1120-1129
|
|
|
Michelucci, R., Pasini, E., Riguzzi, P., Andermann, E., Kälviäinen, R., Genton, P. (2016) Myoclonus and seizures in progressive myoclonus epilepsies: Pharmacology and therapeutic trials. Epileptic Disorders, 18(Suppl 2): 145-153
|
|
|
Minassian, B.A. (2016) Post-modern therapeutic approaches for progressive myoclonus epilepsy. Epileptic Disorders, 18(S2): 154-158
|
|
|
Minassian, B.A. (2001) Lafora's disease: Towards a clinical, pathologic, and molecular synthesis. Pediatric Neurology, 25(1): 21-29
|
|
|
Ortolano, S., Vieitez, I., Agis-Balboa, R.C., Spuch, C. (2014) Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease. Molecular Brain, 7(1): 7-7
|
|
|
Schorlemmer, K., Bauer, S., Belke, M., Hermsen, A., Klein, K.M., Reif, P.S., Oertel, W.H., Kunz, W.S., Knake, S., Rosenow, F., Strzelczyk, A. (2013) Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease). Epilepsy & Behavior Case Reports, 1: 118-121
|
|
|
Steinhoff, B.J. (2014) Efficacy of perampanel: A review of pooled data. Epilepsia, 55(Suppl 1): 9-12
|
|
|
Striano, P., Zara, F., Turnbull, J., Girard, J., Ackerley, C.A., Cervasio, M., de Rosa, G., del Basso-de, C.M.L., Striano, S., Minassian, B.A. (2008) Typical progression of myoclonic epilepsy of the Lafora type: A case report. Nature Clinical Practice Neurology, 4(2): 106-111
|
|
|
Turnbull, J., Tiberia, E., Striano, P., Genton, P., Carpenter, S., Ackerley, C.A., Minassian, B.A. (2016) Lafora disease. Epileptic Disorders, 18(Suppl 2): 38-62
|
|
|
Turnbull, J., Depaoli-Roach, A.A., Zhao, X., Cortez, M.A., Pencea, N., Tiberia, E., Piliguian, M., Roach, P.J., Wang, P., Ackerley, C.A., Minassian, B.A. (2011) PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. PLoS Genetics, 7(4): e1002037-e1002037
|
|
|
|
|